# A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

> **NCT04008797** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eisai Inc.** · enrollment: 301 (estimated)

## Conditions studied

- Endometrial Neoplasms
- Neoplasms
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Colorectal Neoplasms

## Interventions

- **DRUG:** E7386
- **DRUG:** Lenvatinib
- **DRUG:** Doxorubicin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04008797
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-11
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 301 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04008797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04008797, "A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04008797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*